Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02616679 · ClinicalTrials.gov registry record
Cognitive Detection of Preclinical AD: Validation Using Biomarkers
A clinical trial of Mild Cognitive Impairment, sponsored by NYU Langone Health.
- Completed
- Registry status
- 81
- Enrollment target
- 1
- Study location
NCT02616679 is a study of Mild Cognitive Impairment that has completed, run by NYU Langone Health. The registered enrollment target is 81 participants, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02616679, a study of Mild Cognitive Impairment, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 81 participants
- Enrollment target
- 1
- Study location
Study Summary
The current study aims to validate several novel cognitive tasks expected to be sensitive to brain impairment in specific anatomic regions affected in preclinical Alzheimer's disease(pAD). The tasks are validated in 60 cognitively and clinically normal participants ages 60 - 85, inclusive, against reasonably well-established biomarkers of Alzheimer's disease, including 1) simultaneous positron emission tomography (PET) \[18F\]Flutemetamol amyloid and CT imaging and 2) to the extent data is available from other studies, participants' brain MRI and cerebral spinal fluid (CSF) amyloid and tau.
Conditions Studied
Study Locations (1)
New York
- NYU Langone Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2016-01-05 |
| Est. Completion | 2020-08-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02616679
The ClinicalTrials.gov registry entry for NCT02616679 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (94% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 0 interventions.
NCT02616679 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02616679 about?
NCT02616679 is a clinical study titled "Cognitive Detection of Preclinical AD: Validation Using Biomarkers". The current study aims to validate several novel cognitive tasks expected to be sensitive to brain impairment in specific anatomic regions affected in preclinical Alzheimer's disease(pAD). The tasks are validated in 60 cognitively and clinically normal participants ages 60 - 85, inclusive, against r...
What is the current status of trial NCT02616679?
This trial is currently completed. The enrollment target is 81 participants. The study started on 2016-01-05. Estimated completion is 2020-08-12.
What conditions does trial NCT02616679 study?
This clinical trial studies the following conditions: Mild Cognitive Impairment.
Who is sponsoring clinical trial NCT02616679?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02616679 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Wayfinding Intervention and Long-Term Memory
RECRUITING · NA
-
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
RECRUITING · Early Phase 1
-
MCI Speech in Noise
RECRUITING
-
Dual Task Perturbation Training for OAwMCI
RECRUITING · NA
-
Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
RECRUITING
-
Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.